Fig. 3

The effect of liraglutide on the expression of GLP-1R, SPC, Ang-1, and FGF-10 and proliferation of hCMSCs when exposed to LPS for 48 h. Western blot (a): hCMSCs were exposed to LPS from 0 to 30 μg/ml with or without 10 nM liraglutide; RT-qPCR (b–e): values were calculated as the fold change of 2^−△△Ct levels of 0, 1, 10, and 30 μg/ml LPS without liraglutide (liraglutide group versus vehicle group, *P < 0.05, **P < 0.01); MTT assay (f) detected the cell viability of hCMSCs treated with 0, 1, 10, and 30 μg/ml LPS with or without 10 nM liraglutide after 48 h (liraglutide group versus vehicle group, *P < 0.05, **P < 0.01). Data are represented as mean ± SD